ArticleScientific reports2026
FNDC1 is closely related to poor prognosis and immune cell infiltration in gastric cancer.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Multi-Omics Analysis of the Effects ofInternational journal of molecular sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Fibronectin type III domain containing 1 (FNDC1) in gastric cancer (GC) progression and immune cell infiltration remains unclear. This study aimed to investigate the impact of FNDC1 on GC progression and to elucidate its association with immune cell infiltration in GC. FNDC1 expression profiles in GC and paired normal tissues were analyzed using datasets from the TCGA, GTEx, and GEO databases, with validation conducted through quantitative real-time PCR (qPCR) and immunohistochemistry (IHC). Differentially expressed genes (DEGs) associated with FNDC1 were identified through gene set enrichment analysis (GSEA) and functional enrichment analysis. We evaluated the role of FNDC1 in GC immune cell infiltration. In addition, Cox regression and Kaplan-Meier analyses were conducted on FNDC1 for its prognostic significance and correlation with clinical variables. We evaluated the role of FNDC1 in gastric cancer cell invasion and migration via Transwell and wound-healing assays following FNDC1 knockdown and overexpression. Finally, survival probabilities in GC patients were predicted by nomogram construction. FNDC1 expression in GC tissues significantly increased relative to that in matched normal samples (P < 0.001), as confirmed by qPCR and IHC (both P < 0.05). There were 359 DEGs associated with ECM Receptor Interaction, Focal Adhesion, and the Degradation of the Extracellular Matrix signaling pathway. FNDC1 expression was positively related to macrophage and NK cells infiltration (macrophage, r = 0.564, P < 0.001; NK cells, r = 0.566, P < 0.001; as validated by IHC and further confirmed by in vitro co-culture assays). Additionally, FNDC1 expression was strongly related to T stage (P < 0.001), pathological stage (P < 0.001), histological grade (P < 0.01), histological type (P < 0.001), anatomic neoplasm subdivision (P < 0.001), and unfavorable overall survival (OS, P < 0.05). In vitro cell experiments indicate that FNDC1 expression is closely associated with the invasion and migration of gastric cancer cells. Our established nomogram effectively predicted the 1-, 3-, and 5-year OS probabilities in patients with GC (C-index [95% CI] = 0.714 [0.689–0.738]). FNDC1 is strongly associated with a dismal prognostic outcome and immune cell infiltration in patients with GC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.